Insider fund at Crescent Biopharma (NASDAQ: CBIO) buys 1.38M shares, warrants
Rhea-AI Filing Summary
Fairmount Healthcare Fund II L.P., an entity associated with Crescent Biopharma, indirectly purchased 853,450 Ordinary Shares at $14.50 and Pre-Funded Warrants for 525,897 shares at $14.499 on July 16, 2026. The Pre-Funded Warrants are exercisable at $0.001 per share, have no expiration, and are subject to a 9.99% beneficial ownership cap.
After these purchases, Fairmount Healthcare Fund II L.P. indirectly held 3,601,316 Ordinary Shares and Pre-Funded Warrants for 2,294,037 shares. Fairmount Funds Management LLC, Peter Harwin, and Tomas Kiselak disclaim beneficial ownership beyond their pecuniary interest.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Buyer: 853,450 shares
Net Buy
2 txns
Insider
Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Kiselak Tomas, Harwin Peter Evan
Role
Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner
Bought
1,379,347 shs ($20.00M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Pre-Funded Warrant (Right to Buy) F2, F1 | 525,897 | $14.499 | $7.62M |
| Purchase | Ordinary Shares F1 | 853,450 | $14.50 | $12.38M |
Holdings After Transaction:
Pre-Funded Warrant (Right to Buy) — 2,294,037 shares (Indirect, By Fairmount Healthcare Fund II L.P.);
Ordinary Shares — 3,601,316 shares (Indirect, By Fairmount Healthcare Fund II L.P.)
Footnotes (2)
- F1. Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- F2. The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of outstanding shares of common stock of the Issuer immediately after giving effect to such exercise.
Key Figures
Ordinary Shares purchased: 853,450 shares
Pre-Funded Warrants purchased: 525,897 warrants
Aggregate share equivalents bought: 1,379,347 shares
+4 more
7 metrics
Ordinary Shares purchased
853,450 shares
Indirect purchase on July 16, 2026 at $14.500 per Ordinary Share
Pre-Funded Warrants purchased
525,897 warrants
Indirect purchase on July 16, 2026 at $14.499 per warrant (right to buy underlying shares)
Aggregate share equivalents bought
1,379,347 shares
Total of Ordinary Shares and underlying shares of Pre-Funded Warrants purchased
Ordinary Shares held after
3,601,316 shares
Indirect Ordinary Share holdings following July 16, 2026 transactions
Pre-Funded Warrants held after
2,294,037 warrants
Indirect Pre-Funded Warrant holdings following July 16, 2026 transactions
Pre-Funded Warrant exercise price
$0.001 per share
Exercise price for each underlying Ordinary Share under the Pre-Funded Warrants
Beneficial ownership cap
9.99% of outstanding common stock
Maximum beneficial ownership allowed immediately after exercising Pre-Funded Warrants
Key Terms
Pre-Funded Warrants, beneficial ownership, pecuniary interest, director by deputization
4 terms
Pre-Funded Warrants financial
"The Pre-Funded Warrants have no expiration date and are exercisable at any time"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
beneficial ownership financial
"would beneficially own more than 9.99% of the number of outstanding shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest"
director by deputization regulatory
"Fairmount may be deemed a director by deputization of Issuer"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Crescent Biopharma (CBIO) report on July 16, 2026?
Crescent Biopharma reported that Fairmount Healthcare Fund II L.P. indirectly purchased 853,450 Ordinary Shares at $14.50 and Pre-Funded Warrants for 525,897 shares at $14.499 on July 16, 2026, increasing its indirect holdings of both ordinary shares and pre-funded warrants.
How many Crescent Biopharma (CBIO) securities does Fairmount Healthcare Fund II L.P. hold after the transactions?
Following the July 16, 2026 trades, Fairmount Healthcare Fund II L.P. indirectly held 3,601,316 Ordinary Shares and Pre-Funded Warrants for 2,294,037 shares of Crescent Biopharma, as reported under indirect ownership "By Fairmount Healthcare Fund II L.P."
What are the key terms of Crescent Biopharma (CBIO) Pre-Funded Warrants bought by Fairmount?
The Pre-Funded Warrants acquired, representing 525,897 underlying shares, are exercisable at $0.001 per share, have no expiration date, and include a 9.99% beneficial ownership cap that prevents the holder from exceeding that percentage of Crescent Biopharma’s outstanding common stock upon exercise.
Who are the reporting persons in this Crescent Biopharma (CBIO) insider report and how is ownership described?
Reporting persons include Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Peter Harwin, and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest in those holdings.
Were Crescent Biopharma (CBIO) insider purchases made under a Rule 10b5-1 trading plan?
The document-level Rule 10b5-1 checkbox was not marked as affirming plan-based trades, and no footnotes describe a Rule 10b5-1 plan. Accordingly, these purchases are not identified in the report as being executed under a pre-arranged trading plan.